2 Information about upadacitinib

Marketing authorisation indication

2.1 Upadacitinib (Rinvoq, AbbVie) 'is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for upadacitinib.


2.3 The cost of 28 15-mg tablets of upadacitinib is £805.56 (excluding VAT; BNF online, accessed August 2021). The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)